Lactams
Medchemexpress LLC Thalidomide-5-nh2-c8-nh2 tfa | 2097509-49-2 | 98.3% | 514.49 | 100 MG
Thalidomide-5-NH2-C8-NH2 TFA is a chemical compound that can be used for compound synthesis. It is for research purposes only and not for sale to patients.
- Appearance: Solid
- Color: Light yellow to green yellow
- Molecular Formula: C23H29F3N4O6
Apexbio Technology LLC Thalidomide 50-35-1 200mg
Thalidomide (CAS 50-35-1) is a small-molecule inhibitor targeting the CRBN-DDB1-Cul4A E3 ubiquitin ligase complex It is designed to modulate ubiquitination pathways thereby regulating protein degradation cellular proliferation and immune signaling Thalidomide exerts its biological activity primarily through inhibition of the CRBN-DDB1-Cul4A complex In cell-based studies thalidomide demonstrates inhibitory activity with reported IC50 values ranging from approximately 1 M to 100 M depending on the assay and cell line Based on these pharmacological properties thalidomide holds research potential in the fields of immune regulation angiogenesis inhibition and cancer biology particularly in studies of hematological malignancies such as multiple myeloma
Medchemexpress LLC Thalidomide (Standard) | 50-35-1 | 100.0% | 258.23 | 50 MG
Thalidomide (Standard) | 50-35-1 | 100.0% | 258.23 | 50 MG
Medchemexpress LLC VH 101 phenol-alkylC4-amine dihydrochloride | 2564467-03-2 | >95.0% | C30H44Cl2FN5O5S | 10MG
VH 101 phenol-alkylC4-amine dihydrochloride is a von Hippel-Lindau (VHL) protein ligand developed as a building block for PROTAC synthesis and E3 ligase conjugation. Supplied as the dihydrochloride salt, it is intended for research use in targeted protein degradation and conjugation workflows.
- VHL ligand suitable for PROTAC synthesis and E3 ligase recruitment.
- Dihydrochloride salt for improved handling and conjugation chemistry.
- Molecular formula C30H44Cl2FN5O5S; molecular weight 676.67 g/mol.
- Purity reported as ≥95.0% by HPLC in supplier documentation.
- Recommended storage: keep dry at room temperature; in solvent store at -80°C (2 years) or -20°C (1 year).
- Intended for research use in targeted protein degradation and conjugation workflows.
Medchemexpress LLC Thalidomide-O-COOH | 1061605-21-7 | MFCD31560477 | 99.9% | 332.27 g·mol⁻¹ | C15H12N2O7 | 1 G
Thalidomide-O-COOH is a thalidomide-derived small-molecule ligand that recruits the CRBN E3 ubiquitin ligase and is commonly used as the E3 ligase component in PROTAC design and other chemical biology applications.
- Used as a cereblon (CRBN) E3 ligase ligand for PROTAC construction.
- CAS number 1061605-21-7; molecular formula C15H12N2O7; molecular weight 332.27 g·mol⁻¹.
- Reported high purity suitable for research and synthesis workflows.
- Functional handle (carboxylic acid) enables conjugation to linkers and building blocks.
- Supplied as a solid for storage and handling in synthetic and analytical protocols.
Medchemexpress LLC Thalidomide-piperazine-PEG1-COOH | 2731007-11-5 | 99.2% | 458.46 | 25 MG
Thalidomide-Piperazine-PEG1-COOH is a synthetic E3 ligase ligand-linker coupler containing a Thalidomide-based ligand and one linker. It acts as an E3 ligase ligand-linker conjugate.
- E3 ligase ligand-linker coupler
- Contains a Thalidomide-based ligand and one linker
Cayman Chemical -ThalIdomIde 100mg
An immunomodulatory compound with diverse biological activities; prevents PMN chemotaxis at 1, 10, and 100 UG/ml; increases IL-2-induced proliferation and IFN-γ production in primary human T cells in vitro; enhances NK cell-mediated cytotoxicity in MM.1S multiple myeloma cells; reduces lung IL-6, TGF-β, VEGF, angiopoietin-1, angiopoietin-2, and collagen type Iα1 expression, inhibits pulmonary angiogenesis, and attenuates fibrosis in a mouse model of bleomycin-induced pulmonary fibrosis at 4 mg/animal; induces apoptosis in primary human embryonic fibroblasts (EC50 = 8.9 µM) and induces limb and eye defects in chicken embryos (EC50 = 50 UG/kg egg weight)
Medchemexpress LLC Thalidomide-4-F,5-Br | 2740657-28-5 | MFCD34180776 | 99.4% | 355.12 g·mol⁻1 | C13H8BrFN2O4 | 25 MG
Thalidomide-4-F,5-Br is a halogenated thalidomide analogue that functions as an E3 ligase recruiting ligand for targeted protein degradation research. Supplied as a powder in small pre-weighed quantities, it is intended for research use in PROTAC development and studies of ubiquitin-mediated proteolysis.
- Halogenated thalidomide derivative (fluoro and bromo substitutions).
- Acts as a cereblon (CRBN) E3 ligase recruiting ligand for PROTAC applications.
- High purity suitable for research (approximately 99.4%).
- Provided as a powder for easy handling and formulation.
- Available in small pre-weighed quantities for screening and synthesis workflows.
eMolecules Thalidomide-5-(PEG4-amine) | Broadpharm |520.539 | C24H32N4O9 | 0.000 | NCCOCCOCCOCCOCCNC(=O)c1ccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c2c1 | 100mg | 713699642
Thalidomide-5-(PEG4-amine) | Broadpharm |520.539 | C24H32N4O9 | 0.000 | NCCOCCOCCOCCOCCNC(=O)c1ccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c2c1 | 100mg | 713699642
Medchemexpress LLC Thalidomide-O-PEG4-azide | 2380318-57-8 | 98.0% | C23H29N5O9 | 100 MG
Thalidomide-O-PEG4-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the thalidomide based cereblon ligand and a linker used in PROTAC technology. It is a click chemistry reagent, containing an azide group that can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing alkyne groups, and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
- Synthesized E3 ligase ligand-linker conjugate
- Incorporates thalidomide based cereblon ligand
- Used in PROTAC technology
- Click chemistry reagent containing an azide group
- Undergoes copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc)
- Undergoes strain-promoted alkyne-azide cycloaddition (SPAAC)
- Molecular weight of 519.50
- Appears as a colorless to light yellow oil
Medchemexpress LLC Thalidomide-5-NH2-CH2-COOH | 2412056-27-8 | 95.0% | C15H13N3O6 | 500 MG
Thalidomide-5-NH2-CH2-COOH (compound 114) is a potent and selective inhibitor of tropomyosin receptor kinase (Trk) and a ligand of E3 ligase. It has potential for researching various diseases, as extracted from patent WO2021170109A1.
- Potent and selective Trk inhibitor
- Ligand of E3 ligase
- Researches various diseases including cancer, inflammation, and neurodegenerative conditions
- Solid appearance
- Color can range from light yellow to green yellow
![Medchemexpress LLC 5,8,11-Trioxa-2-azatridecanoic acid, 13-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl)amino]-, 1,1-dimethylethyl ester | 2204246-03-5 | 97.2% | 548.59 | 5 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000403850-logo.png-250.jpg){kind=logo}
Medchemexpress LLC 5,8,11-Trioxa-2-azatridecanoic acid, 13-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl)amino]-, 1,1-dimethylethyl ester | 2204246-03-5 | 97.2% | 548.59 | 5 MG
Thalidomide-NH-PEG3-NH-Boc is a chemical compound that appears as a light yellow to yellow oil. This product has been thoroughly tested and complies with the given specifications, ensuring its quality and suitability for research purposes.
- Molecular formula: C26H36N4O9
- Molecular weight: 548.59
- Purity (LCMS): 97.20%
- Storage for pure form: -20°C for 3 years; 4°C for 2 years
- Storage in solvent: -80°C for 6 months; -20°C for 1 month
Medchemexpress LLC Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride | 2341841-02-7 | 99.3% | 410.81 | 25 MG
Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. This compound is suitable for designing PROTACs.
- Incorporates a cereblon (CRBN) ligand for E3 ubiquitin ligase
- Contains a linker
- Suitable for designing PROTACs
- Relevant to cancer targeted therapy, cancer metabolism, and metastasis
- Related to PROTAC research
- Involved in autophagy studies
- Used in apoptosis research
- Applicable to E3 ligase ligand-linker conjugates
Medchemexpress LLC Thalidomide-Piperazine-PEG3-COOH | 2797619-63-5 | 99.89% | 546.57 | 25 MG
A synthesized ligand-linker conjugate is described as incorporating a cereblon ligand and a linker often employed in protein degradation technology. This conjugate is intended for research applications only and not for patient use.
- Synthesized conjugate.
- Incorporates a cereblon ligand.
- Utilizes a linker as part of protein degradation technology.
- Composed of two distinct ligands joined by a linker.
- One ligand targets an E3 ubiquitin ligase.
- The other ligand targets a specific protein.
- Leverages the intracellular ubiquitin-proteasome system.
- Aims for selective degradation of target proteins.
- For research purposes only.